ConductScience.org, home

Comparison · NCT00349908-sae

Group 1: Atherosclerosis Arm vs Group 2: Aneurysm Arm: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Group 1: Atherosclerosis Arm vs Group 2: Aneurysm Arm: serious adverse events. Trial comparisons, record NCT00349908-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00349908-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.30.1080.603wilson
Risk in group 20.30.1080.603wilson
Risk difference, group 1 minus group 20-0.3590.359newcombe hybrid score
Risk ratio, group 1 over group 210.2623.81log
Odds ratio, group 1 over group 210.1486.77log
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Group 1: Atherosclerosis ArmThis is the events from the Atherosclerosis Arm310EG000
Group 2Group 2: Aneurysm ArmThis is the events from the Aneurysm Arm310EG001

Harm

What it counts
Total, serious adverse events
Time frame
From the time the informed consent was signed, AEs were assessed after the procedure, at discharge, at thirty days and six months after treatment.

Source ClinicalTrials.gov

Trial

Title
A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries
NCT number
NCT00349908
Phases
PHASE1
Conditions
Atherosclerosis, Aneurysm
Interventions
Cordis Neurovascular ENTERPRISE Self Expanding Stent System, Cordis Neurovascular ENTERPRISE Self Expanding Stent System
Lead sponsor
Codman & Shurtleff
Results first posted
2013-10-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00349908-sae